Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
About Alnylam Pharmaceuticals
Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.
Company Facts
- Headquarters
- Cambridge
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- public
- Employees
- c_01001_05000
- Funding Stage
- ipo
- Total Funding
- $4,545,850,000
- Last Funding Type
- post_ipo_debt
- Last Funding Date
- 2025-09-09
- Website
- alnylam.com
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
Social Links
Canonical: https://fsome.com/organization/alnylam-pharmaceuticals-23673 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.